1007884-79-8

Upstream product

• 1007884-76-5 (2S)-2-(1-(4-bromophenyl)-3-ethoxy-1,3-dioxopropan-2-yl) 1-tert-butyl pyrrolidine-1,2-dicarboxylate 
• 15761-39-4 1-(tert-butoxycarbonyl)-L-proline 

Downstream Products

• 1007884-81-2 (S)-tert-butyl 2-(5-(4-bromophenyl)-4-(methylcarbamoyl)-1H-imidazol-2-yl)pyrrolidine-1-carboxylate 
• 1319190-95-8 C₂₇H₄₀BrN₃O₅Si 
• 1319191-81-5 C₂₅H₃₆BrN₃O₄Si 
• 1319190-96-9 C₂₅H₃₈BrN₃O₄Si 
• 1319190-99-2 C₂₈H₄₂BrN₃O₄Si 
• 1319191-03-1 C₂₄H₂₉BrN₄O₄ 
• 1319191-04-2 C₂₂H₂₅BrN₄O₄ 
• 1319192-09-0 C₄₀H₄₇N₇O₆ 
• 1319190-32-3 C₄₂H₅₀N₈O₇ 
• 1319184-72-9 C₄₂H₅₂N₈O₇ 
• 1319191-45-1 C₂₈H₄₀BrN₃O₄Si 

Relevant academic research and scientific papers

HEPATITIS C VIRUS INHIBITORS

The present invention discloses compounds of Formula (I), and pharmaceutically acceptable salts, esters, or prodrugs thereof: (structurally represented), which inhibit RNA-containing virus, particularly the hepatitis C virus (HCV). Consequently, the compounds of the present invention interfere with the life cycle of the hepatitis C virus and are also useful as antiviral agents. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from HCV infection. The invention also relates to methods of treating an HCV infection in a subject by administering a pharmaceutical composition comprising the compounds of the present invention.

HEPATITIS C VIRUS INHIBITORS

The present invention discloses compounds of Formula (I), and pharmaceutically acceptable salts, esters, or prodrugs thereof: Q-G-A-L-B-W (I) which inhibit RNA-containing virus, particularly the hepatitis C virus (HCV). Consequently, the compounds of the

Hepatitis C Virus Inhibitors

The present disclosure relates to compounds, compositions and methods for the treatment of hepatitis C virus (HCV) infection. Also disclosed are pharmaceutical compositions containing such compounds and methods for using these compounds in the treatment of HCV infection.